June 30, 2016
GlycoBiomarker Leading Innovation Co. Ltd.
GL-i was selected for “2016 Project for promoting bridging research for small- and medium-sized companies” by New Energy and Industrial Technology Development Organization (NEDO)
GlycoBiomarker Leading Innovation Co. Ltd. (GL-i) was selected for “2016 Project for promoting bridging research for small- and medium-sized companies” by New Energy and Industrial Technology Development Organization (NEDO) and will pursue commercialization of high performance assay of disease-related glycobiomarkers in collaboration with the National Institute of Advanced Industrial Science and Technology (AIST).
Commercialization of high performance assay technology for disease related glycobiomarkers
Glycans of glycoproteins secreted from disease cells indicate characteristic structures and thus are broadly expected to be used as biomarkers. In this project, the core institute, Glycomedicine R&D Group of GL-i (CTO and Prime Senior Researcher, Atsushi Kuno; project leader) and the transferring institute, Biotechnology Research Institute for Drug Discovery of AIST (Principal Research Manager, Hisashi Narimatsu) will efficiently develop high performance assay kits for disease glycobiomarkers under the globally competitive developmental network, which has been established with several universities and companies.
Achievements of this project will greatly encourage rapid commercialization of in vitro diagnostics (laboratory test drugs) using glycoproteins, which are attracting much attention recently. Unlike conventional diagnostics based on the substances secreted from degraded disease cells, novel diagnostics consisting of glycobiomarkers that reflect the state of disease cells have a high signal-to-noise (S/N) ratio. This feature is ideal for early detection of disease, stratification of the patients diagnosed with a same disease, and accuracy improvement of drug efficacy evaluation, which will efficiently support selection of appropriate therapeutic strategy and development of therapeutic drugs.
July 8, 2016 to December 28, 2017
This project encourages small- and medium-sized businesses and start-ups (SMBs) as well as associations to improve their technology and rapidly advance their production through transfer and commercialization of technical seeds developed in research institutes (transferring institutes) and realization of SMBs’ technologies with support of the research institutes. In addition, the support by NEDO will stimulate similar activity of the transferring institutes. For FY2016 (application period: March 22 to May 10, 2016; selected on June 30, 2016), 23 applicants were selected from 92 proposals. Please refer to the link to find out the project outline and selected themes. (NEDO website in Japanese)
GlycoBiomarker Leading Innovation Co. Ltd. (GL-i)
1-1-1 Umezono, Tsukuba, Ibaraki 305-8568 Japan
E-mail: email@example.com / URL: http://www.gl-i.co.jp/en/index_e.html